Wockhardt: Clinical Trials

7 trials sponsored by Wockhardt, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 withdrawn, 1 not yet recruiting, 1 terminated. 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 37Completed 2, Withdrawn 2, Not yet recruiting 1, Terminated 1, Unknown 1

Follow Wockhardt: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cefepime-Zidebactam Versus Ceftazidime-Avibactam With or Without Colistin for Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Cefepime-Zidebactam, Ceftazidime-avibactam with or without Colistin - Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP)
Phase 3Not yet recruitingWockhardt3242026-10-282026-10-21
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
WCK 4282 (FEP-TAZ) 4 g, Meropenem, ciprofloxacin 500 mg Optional Oral Switch - Complicated Urinary Tract Infection, Acute Pyelonephritis
Phase 3UnknownWockhardt10042024-01-012023-07-17
Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Cefepime-zidebactam (FEP-ZID), Meropenem - Complicated Urinary Tract Infection, Acute Pyelonephritis
Phase 3CompletedWockhardt5302022-08-282026-05-22
Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Oral Levonadifloxacin/Linezolid Tablet, Intravenous Levonadifloxacin/Linezolid Infusion - Acute Bacterial Skin and Skin Structure Infections
Phase 3CompletedWockhardt5012017-08-252020-06-29
Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics
Insulin Lispro - Type I Diabetes
Phase 3WithdrawnWockhardt2012-02-012013-01-25
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
Wosulin (N or 70/30 with R), NovolinĀ® (N or 70/30 with R) - Type I Diabetes
Phase 3TerminatedWockhardt1342011-03-012023-06-23
Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients
Wockhardt's Insulin Analogue (Recomb), LantusĀ® - Type I Diabetes
Phase 3WithdrawnWockhardt2019-10-08

Conditions studied

Diabetes Mellitus, Type 1 (3)

Interventions

Meropenem (2)  ·  cefepime-zidebactam (2)  ·  Ciprofloxacin (1)  ·  Colistin (1)  ·  Insulin (1)  ·  Insulin Glargine (1)  ·  Insulin Lispro (1)  ·  Linezolid (1)  ·  avibactam, ceftazidime drug combination (1)  ·  levonadifloxacin (1)

Countries

India (4)  ·  Bulgaria (2)  ·  Lithuania (2)  ·  Poland (2)  ·  United States (2)  ·  Bosnia and Herzegovina (1)  ·  China (1)  ·  Croatia (1)  ·  Estonia (1)  ·  France (1)  ·  Georgia (1)  ·  Greece (1)  ·  Italy (1)  ·  Mexico (1)  ·  Moldova (1)

Top investigators

Ashima Bhatia, M.D. (1)  ·  Dr Ashima Bhatia, M.D. (1)  ·  Dr.Rasendrakumar Jha (1)  ·  Manishkumar D Shah, PhD (1)  ·  Rakesh Chugh, MD (1)

Results publications

PMID 32738837, PMID 33332545